Personalized management of patients with inoperable alveolar echinococcosis undergoing treatment with albendazole: usefulness of positron-emission-tomography combined with serological and computed tomography follow-up.
The present study aimed to identify a sub-group of inoperable alveolar echinococcosis (AE) patients undergoing long-term treatment with benzimidazole (BZM) who presented with an evolution suggestive of a parasitocidal effect. An evolution compatible with parasite death was observed in five patients.
Crouzet
J
J
WHO Collaborating Center for Prevention and Treatment of Human Echinococcosis, University Hospital, Besançon, France.
Grenouillet
F
F
Delabrousse
E
E
Blagosklonov
O
O
Thevenot
T
T
Di Martino
V
V
Piarroux
R
R
Mantion
G A
GA
Bresson-Hadni
S
S
D000328:Adult; D015766:Albendazole / Q000627:therapeutic use*; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D000909:Antibodies, Helminth / Q000097:blood; D016903:Drug Monitoring / Q000379:methods*; D004443:Echinococcosis; D004444:Echinococcosis, Hepatic / Q000175:diagnosis / Q000188:drug therapy; D004446:Echinococcus / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D011860:Radiography, Abdominal / Q000379:methods; D012698:Serologic Tests; D014057:Tomography, X-Ray Computed / Q000379:methods
D000871:Anthelmintics; D000909:Antibodies, Helminth; D015766:Albendazole